Clinical Trial

Rectosigmoid Lesion Excision vs. Resection: A Non-Inferiority Randomized Comparison in Advanced Ovarian Cancer

Study acronym: RSEnTrail
Recruiting
View on ClinicalTrials.gov →
Summary
Colorectum is the most common site of metastasis in ovarian cancer. Regarding intestinal surgery, there is controversy over whether to choose bowel resection or tumor removal, and currently, there are no prospective randomized controlled studies comparing the oncological safety of these two surgical approaches. This study is a prospective randomized trial aimed at comparing the efficacy of rectosigmoid resection versus rectosigmoid-preserving lesion excision in advanced ovarian cancer surgery.
Protocol Amendment History 1 change
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
Trial Details
NCT Number NCT07616310
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators: Tongji Hospital, Zhejiang University, Zhejiang Provincial People's Hospital, Zhejiang Cancer Hospital, Huzhou Central Hospital, Ningbo Women & Children's Hospital, Shaoxing People's Hospital, The Central Hospital of Lishui City, Women's Hospital School Of Medicine Zhejiang University
Conditions Ovarian Cancer (OvCa)
Enrollment 300 participants
Start Date 2024-01-10
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-01